On November 16, 2026 Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), reported the financial results for the third quarter ended September 30, 2026, and highlighted continued progress across its clinical development programs, including completion of treatment in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin (also known as naxtarubicin) in relapsed or refractory acute myeloid leukemia (AML).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Moleculin continues to advance its lead clinical program following completion of treatment for all 90 patients in Part A of the MIRACLE trial. The Company remains on track to report comprehensive Part A data in the first quarter of 2027. These data are expected to support selection of the optimal Annamycin dose for advancement into Part B, which is currently planned to begin in the first half of 2027.
"We are approaching one of the most important milestones in Moleculin’s development, and I believe our progress has positioned us to enter 2027 with meaningful momentum," said Walter Klemp, Chairman and Chief Executive Officer of Moleculin. "Completing treatment of all 90 patients in Part A of our pivotal MIRACLE trial is a significant execution achievement. We are now focused on delivering the comprehensive dataset in the first quarter of 2027, which we expect will provide important insights into Annamycin’s clinical activity, safety and optimal dose for advancement into Part B. We are also looking forward to releasing quantitative market research data soon, further supporting the commercial opportunity for Annamycin "
"What gives us confidence as we approach this readout is the totality of evidence generated to date," continued Mr. Klemp. "We have reported encouraging interim clinical findings, strengthened the scientific foundation supporting Annamycin’s differentiated cardiac safety profile through independent, peer-reviewed analysis, and continued to execute against our pivotal development strategy. We believe Annamycin has the potential to address a meaningful treatment gap in AML, and the upcoming Part A results represent an important opportunity to further evaluate that potential. Our priority is clear: execute on the data readout, make informed development decisions and advance Annamycin toward its next critical milestones."
Recent Highlights
Completed treatment for all 90 patients in Part A of the Phase 2/3 MIRACLE trial evaluating Annamycin in combination with cytarabine for relapsed or refractory AML. The Company remains on track for a comprehensive data readout in the first quarter of 2027. The full Part A dataset is expected to inform optimal dose selection for the planned initiation of Part B.
Published a peer-reviewed analysis in Frontiers in Cardiovascular Medicine evaluating cardiac safety findings from 90 patients treated with Annamycin across five clinical trials in AML and metastatic soft tissue sarcoma. The analysis, independently evaluated by a cardio-oncology laboratory at Cleveland Clinic, found no clinical or subclinical evidence of treatment-related cardiotoxicity, including at cumulative Annamycin exposures exceeding traditional lifetime limits for conventional anthracyclines.
Presented new preclinical data at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Conference on Pancreatic Cancer indicating that Annamycin’s antitumor activity in pancreatic cancer models is partially mediated by CD8+ T cell cytotoxicity. These findings suggest Annamycin may help expose immunologically "cold" tumors to immune attack, potentially supporting combination treatment approaches.
Announced acceptance of data from the MIRACLE trial for presentation at the 2026 American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting. The presentation will highlight interim results from the pivotal Phase 2/3 trial in patients with relapsed or refractory AML.
Expected Milestones for the Annamycin Development Program
Q1 2027: MIRACLE – Comprehensive Part A data readout following completion of treatment for all 90 patients
1H 2027: MIRACLE – Planned initiation of Part B following optimal dose selection
1H 2027: Planned initiation of physician-sponsored clinical trial evaluating Annamycin for pancreatic cancer
1H 2028: Planned initiation of third-line relapsed/refractory AML subject trial
1H 2028: Planned initiation of pediatric AML clinical study
2H 2028: Complete recruitment of Part B
2H 2028: Primary efficacy data for MIRACLE 2nd line subjects
2028-2029: Begin a rolling submission of a New Drug Application (NDA) for the treatment of R/R AML for accelerated approval on primary endpoint of CR from MIRACLE
Additional Pipeline Programs
Moleculin continues to support development activities for its WP1066 program through investigator-sponsored research, including a physician-sponsored Phase 1B/2 clinical trial evaluating WP1066 in combination with radiation for the treatment of glioblastoma. These programs complement Moleculin’s primary focus on advancing Annamycin.
Third Quarter 2026 Financial Results
Research and development expenses were approximately $4.5 million for the three months ended September 30, 2026, compared to approximately $3.7 million for the same period in 2025. The increase was primarily attributable to activities related to the MIRACLE clinical trial.
General and administrative expenses were approximately $2.1 million for the three months ended September 30, 2026, compared to approximately $2.1 million for the same period in 2025.
Net loss for the third quarter of 2026 was approximately $6.5 million, compared to approximately $25.4 million for the same period in 2025. The decrease in net loss was primarily attributable to the absence of the approximately $20.6 million non-cash loss on the issuance of warrant liabilities recorded in the prior-year period.
For the nine months ended September 30, 2026, research and development expenses were approximately $15.3 million, compared to approximately $10.8 million for the same period in 2025. The increase was primarily related to the MIRACLE clinical trial, additional nonclinical studies and other research costs. General and administrative expenses were approximately $6.7 million for the nine months ended September 30, 2026, compared to approximately $6.7 million for the same period in 2025.
As of September 30, 2026, Moleculin had cash and cash equivalents of approximately $7.3 million, compared to approximately $8.9 million as of December 31, 2025. Net cash used in operating activities for the nine months ended September 30, 2026 was approximately $21.7 million.
(Press release, Moleculin, NOV 16, 2026, View Source [SID1234674795])